We are also further exploring its potential use as an AML MRD marker and hoping this study will create interest from others to additionally evaluate if CD9 will be a robust marker for AML MRD assessment in non-APL subtypes. The gene discussed is CD9; the disease is acute promyelocytic leukemia.